Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature.

Cancer reports (Hoboken, N.J.) - 1 Aug 2024

Silva Klerize Anecely de Souza, Magalhães Isis Maria Quezado Soares, Benincasa Daniela Elaine Roth, Cecconello Daiane Keller, Michalowski Mariana Bohns

Abstract excerpt

BACKGROUND: Langerhans cell histiocytosis (LCH) is a clonal myeloid neoplasm with inflammatory component. Refractory disease is a challenge, but vemurafenib has emerged as a therapeutic option. We will delineate the cases of two Brazilian children suffering from refractory LCH with a positive response to vemurafenib. CASES: Both cases had a diagnosis of multisystem disease with involvement of organs at risk and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Brazil

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histiocytosis, Langerhans-Cell

Share to Infant

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins B-raf

Share to Treatment Outcome

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 39190425
DOI: 10.1002/cnr2.2142
PMCID: PMC11348861

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature.PMID 39190425Read ↗

Targeted Therapy with Vemurafenib in Brazilian Children with Refractory Langerhans Cell Histiocytosis: Two Case Reports and a Comprehensive ReviewSemantic proximity Read ↗

Refractory multisystem Langerhans cell histiocytosis in an infant: use of vemurafenib as a therapeutic option.Semantic proximity Read ↗

Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.Semantic proximity Read ↗

Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study.Semantic proximity Read ↗

Failure of salvage vemurafenib therapy for refractory multisystem Langerhans cell histiocytosis with BRAF-V600E mutationSemantic proximity Read ↗

Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.Semantic proximity Read ↗

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.Semantic proximity Read ↗

[Updated AWMF Guideline on the Diagnosis and Treatment of Langerhans cell Histiocytosis in Children and Adolescents].Semantic proximity Read ↗

Cutaneous adverse events in children treated with vemurafenib for refractory BRAFV600E mutated Langerhans cell histiocytosis.Semantic proximity Read ↗

Early association of Vemurafenib to standard chemotherapy in multisystemic Langerhans cell histiocytosis in a newborn: take the chance for a better outcome?Semantic proximity Read ↗

An effective treatment in Erdheim Chester disease: vemurafenib: a case report.Semantic proximity Read ↗

Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.